Preferred Label : eltrombopag;

MeSH note : an oral, nonpeptide thrombopoietin receptor agonist;

CISMeF synonym : SB-497 115; promacta; revolade;

MeSH synonym : (1,1'-biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-;

MeSH hyponym : SB497115; SB-497-115;

Is substance : O;

UNII : S56D65XJ9G;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/eltrombopag-viatris
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
eltrombopag
eltrombopag
drugs, generic

---
https://www.has-sante.fr/jcms/p_3151443/fr/revolade
2020
false
false
false
France
eltrombopag
eltrombopag
thrombocytopenia
Thrombocytopenia Due to Immune Destruction
administration, oral
evaluation of the transparency committee
hydrazines
pyrazoles
benzoates

---
http://www.has-sante.fr/portail/jcms/c_2752842/fr/revolade-pti-adulte-non-splenectomise-pti-enfant-ri-pti-adulte-splenectomise
https://www.has-sante.fr/portail/jcms/c_2752842/fr/revolade-eltrombopag-agonistes-des-recepteurs-a-la-thrombopoietine-pti-adulte-non-splenectomise-pti-enfant-ri-pti-adulte-splenectomise
2017
false
France
French
English
corticosteroid therapy
child
chronic idiopathic thrombocytopenic purpura, nos
Product containing precisely eltrombopag 75 milligram/1 each conventional release oral tablet (clinical drug)
guidelines for drug use
eltrombopag
hydrazines
pyrazoles
benzoates
receptors, thrombopoietin
administration, oral
eltrombopag
insurance, health, reimbursement
orphan drug production
adult
purpura, thrombocytopenic, idiopathic
chronic disease
splenectomy
continuity of patient care
treatment outcome
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_2748397/fr/revolade
2017
false
false
false
France
French
evaluation of the transparency committee
eltrombopag
eltrombopag
administration, oral
Product containing precisely eltrombopag 75 milligram/1 each conventional release oral tablet (clinical drug)
Product containing eltrombopag (medicinal product)
tablets
Oral Suspension Dosage Form
hydrazines
pyrazoles
benzoates

---
http://www.has-sante.fr/portail/jcms/c_2671734/fr/revolade-ams
http://www.has-sante.fr/portail/jcms/c_2671734/fr/revolade-eltrombopag-agoniste-des-recepteurs-a-la-thrombopoietine-ams
2016
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
guidelines for drug use
eltrombopag
eltrombopag
administration, oral
eltrombopag
anemia, aplastic
adult
receptors, thrombopoietin
hydrazines
pyrazoles
benzoates
hydrazines
pyrazoles
benzoates

---
REVOLADE (eltrombopag) - Risk of Severe Hepatotoxicity
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59916a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
Chemical and Drug Induced Liver Injury
eltrombopag
eltrombopag
guidelines for drug use
continuity of patient care
drug monitoring
administration, oral
alanine transaminase
aspartate aminotransferases
bilirubin
blood chemical analysis
product surveillance, postmarketing
canada
patient education handout
hydrazines
pyrazoles
benzoates

---
http://www.has-sante.fr/portail/jcms/c_2015425/fr/revolade
2015
true
France
French
English
chronic idiopathic thrombocytopenic purpura, nos
eltrombopag
hydrazines
pyrazoles
benzoates
receptors, thrombopoietin
administration, oral
eltrombopag
insurance, health, reimbursement
orphan drug production
adult
purpura, thrombocytopenic, idiopathic
chronic disease
splenectomy
continuity of patient care
treatment outcome
evaluation of the transparency committee

---
https://www.ema.europa.eu/medicines/human/EPAR/Revolade
2012
United Kingdom
English
French
syndication feed
splenectomy
treatment outcome
drug approval
drug labeling
continuity of patient care
drug interactions
pregnancy
breast feeding
hemostatics
hemostatics
drug evaluation, preclinical
eltrombopag
hydrazines
pyrazoles
eltrombopag
benzoates
orphan drug production
hydrazines
benzoates
pyrazoles
eltrombopag
administration, oral
adult
purpura, thrombocytopenic, idiopathic
chronic disease
hydrazines
pyrazoles
benzoates
summary of product characteristics
package leaflet
drug evaluation

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61736230
2012
France
summary of product characteristics
package leaflet
eltrombopag
tablets

---
http://www.meddispar.fr/Medicaments/REVOLADE-25-B-14/(type)/letter/(value)/R/(cip)/3400937458580
France
French
eltrombopag
administration, oral
drug prescriptions
legislation, drug
pyrazoles
hydrazines
continuity of patient care
eltrombopag
benzoates
drug information

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60757264
2012
France
summary of product characteristics
package leaflet
eltrombopag
tablets

---
http://www.meddispar.fr/Medicaments/REVOLADE-50-B-28/(type)/letter/(value)/R/(cip)/3400937458931
2011
France
French
hydrazines
pyrazoles
benzoates
drug prescriptions
eltrombopag
legislation, drug
continuity of patient care
administration, oral
eltrombopag
drug information

---
http://www.has-sante.fr/portail/jcms/c_969539/revolade
http://www.has-sante.fr/portail/jcms/c_992378/revolade-eltrombopag-agoniste-des-recepteurs-a-la-thrombopoietine
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-07/revolade_-_ct-8151.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/revolade_ct_8151.pdf
2010
France
French
English
corticosteroid therapy
eltrombopag
hydrazines
pyrazoles
benzoates
receptors, thrombopoietin
administration, oral
eltrombopag
insurance, health, reimbursement
orphan drug production
adult
purpura, thrombocytopenic, idiopathic
chronic disease
splenectomy
continuity of patient care
treatment outcome
hydrazines
pyrazoles
benzoates
evaluation of the transparency committee
guidelines for drug use

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.